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Abstract
Purpose We compared the pharmacokinetics of chloro-
quine in pregnant and nonpregnant women treated for
Plasmodium vivax malaria.
Methods Twelve pregnant women and 15 nonpregnant
women of child-bearing age with acute P. vivax malaria
were treated with 25 mg chloroquine base/kg over 3 days
on the northwestern border of Thailand. Blood concen-
trations of chloroquine and desethylchloroquine were
measured using hydrophilic interaction liquid chromatog-
raphy coupled with fluorescence detection. Twenty-five
women completed the pharmacokinetic study.
Results Although increasing gestational age was associated
with reduced chloroquine AUC0!1, there was no signifi-
cant difference overall in the pharmacokinetics of chloro-
quine between pregnant and nonpregnant women. Fever
was associated with lower chloroquine AUC0!1 values.
Desethylchloroquine area under the curve (AUC) values
were not significantly affected by pregnancy.
Conclusions Pregnancy did not significantly affect blood
concentrations of chloroquine or its metabolite, desethyl-
chloroquine, in women with P. vivax malaria.
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Introduction
Chloroquine remains the prophylactic and treatment of
choice for Plasmodium vivax, P. malariae, and P. ovale
malarias. Pregnancy affects the pharmacokinetic (PK)
properties of the majority of antimalarial drugs [1–7].
Optimal dosing is essential to prevent anemia and low
birth weight [8, 9]. There are very few PK data on
chloroquine (CQ) in pregnancy; two studies involving four
and five women, respectively, gave conflicting results [10,
11]. We therefore assessed CQ PKs in pregnant women
with acute vivax malaria in an area where resistance to CQ
in P. vivax has not yet been documented.
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Methods
This study was conducted in an area of low seasonal
malaria transmission along the northwestern border of
Thailand. In Maela refugee camp, the Shoklo Malaria
Research Unit (SMRU) encouraged all pregnant women to
attend weekly antenatal clinics (ANC) to detect and treat all
parasitemic episodes.
Patients
Pregnant women and nonpregnant women of child-bearing
age with microscopically confirmed P. vivax infection,
fever, or a history of fever, who provided informed
consent, were invited to participate. Otherwise healthy
pregnant women with a gestational age ≥ 20 weeks and ≤
32 weeks and a hematocrit of > 25% were enrolled. A full
medical history and examination was carried out by a
physician and a midwife. Complete blood count, blood
glucose, blood group, and parasite count were measured
on admission.
Drug regimen
Twenty-five milligrams of CQ base/kg (Chloroquine®,
ACDHON CO., Ltd, Bangkok, Thailand) was given over
3 days as 10, 10, and 5 mg/kg doses given strictly, under
observation, at 0, 24, and 48 h.
Sampling
Women were admitted to the SMRU inpatient department.
A heparinized cannula was inserted into an antecubital vein,
and a blood sample (1 ml) was taken immediately before
treatment and then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and
24 h. On days 2, 3, 7, 14, 21, 28, 35, and 42, 1-ml samples
were obtained by direct venous sampling. Samples included
baseline hematology and biochemistry and follow-up
hematology on days 0, 3, 7, 14, 28, and 42.
Ethical review
The study was approved by the Ethical Committee of the
Faculty of Tropical Medicine, Mahidol University, Bang-
kok, Thailand; the Karen Refugee Committee in Mae Sod,
Thailand; and the ethics committee of the London School
of Hygiene and Tropical Medicine, London, UK.
Follow-up
Malaria smears and axillary temperature measurements
were taken daily. After parasite clearance, women were
seen weekly and followed up for 6 weeks. If P. vivax
malaria recurred, the patient was retreated with CQ. All
cases of P. falciparum malaria were treated with quinine or
artesunate [2].
Drug assays
A liquid/liquid extraction method using N-hexane/isopropyl
alcohol and sodium hydroxide (NaOH), previously validat-
ed in our lab, was applied to whole-blood samples (100 µl);
4-aminoquinaldine was used as internal standard, and CQ
and desethylchloroquine (DEQ) were quantified using
fluorescence detection (excitation 335 nm; emission
390 nm). Compound separation was performed on a silica
stationary phase (Waters 3.9×390 nm) using a mobile
phase composed of acetonitrile/methanol and triethylamine.
Linearity, interday, and intraday variability of the method
were validated. None of the coefficients of variation for CQ
and DEQ was above 10% (data not shown). The lower
limits of quantification (LLOQ) for CQ and DEQ were
15 ng/ml whole blood.
Pharmacokinetic analysis
PK parameters of CQ and its main metabolite, DEQ, were
determined using noncompartmental analysis. Peak whole-
blood concentrations and tmax were estimated from the first
24 h data. If levels were below the LLOQ, then the terminal
phase was characterized by a log linear fit to the last five
time points. A sensitivity analysis was conducted by
assessing the area under the curve (AUC) in two other
ways: by setting all concentration measurements that were
not detected to 0 (i.e., assuming clearance of all CQ) and by
comparing AUCs that were calculated from 0 to the
maximum value of time available. Results were the same
regardless of how the “not detected” measurements were
managed. Therefore, only results using interpolated values
are reported.
Statistical analyses
Chi-square or Fisher’s exact test was used for categorical
data. Student’s t test and the Mann–Whitney U test were
used for continuous data. Days 28 and 42 cure rates are
presented as Kaplan–Meier estimates, and differences
between groups were compared using the log rank test
or the Wilcoxon-Breslow-Gehan test of equality if the
survival lines crossed. Univariate analyses were con-
ducted to check for potential covariates. Variables that
had a significant effect on AUC were included in an
analysis of variance (ANOVA) that tested for any dif-
ferences between pregnant and nonpregnant women. All
analyses were carried out using STATA, version 9.0
(StataCorp LP, TX, USA).
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Results
From 2 March 1998 to 10 August 1998, 12 pregnant
women and 15 nonpregnant Karen women of child-bearing
age with acute vivax malaria consented to participate. Two
nonpregnant women withdrew before completion of the
study; their results were not analyzed. Another woman,
initially screened as nonpregnant, had a positive pregnancy
test on day 35 (i.e., she had been enrolled at 2.4 weeks after
her last menstrual period). Her results were analysed in the
nonpregnant group as originally assigned. Two women
gave birth before 42 days (days 23 and 28). No postpartum
samples were analyzed. On admission, there were no
significant differences in demographic characteristics be-
tween pregnant and nonpregnant women (Table 1).
Pregnant women had lower mean hematocrit, lymphocyte
count, and biochemical parameters (i.e., creatinine, blood urea
nitrogen (BUN), and albumin) than did nonpregnant women
(Table 1), consistent with the physiological changes of
pregnancy. The higher bilirubin levels in nonpregnant women
may indicate they had more serious malaria infections [12,
13]. Chloroquine was well tolerated and rapidly effective. The
cure rate at day 28 (n=25) was 100% (95% confidence
interval (CI) 86.7–100). The day 42 cure rate was comparable
in pregnant [83.3% (95% CI 48.2–95.6)], and nonpregnant
[69.2% (95% CI 37.3–87.2)] women (p=0.52).
Pharmacokinetics of chloroquine
Eight women had late measurements that were below the
LLOQ (one pregnant, two values; seven nonpregnant, 12
values). Therefore, these values were extrapolated from the
log linear fit to the available concentration measurements
from the last five time points. In the univariate and
multivariate analyses, for AUC0!3, there was no difference
between pregnant and nonpregnant women (p=0.32)
(Fig. 1, Table 2). There was no effect of hematocrit (p=
0.11), BMI (p=0.60), or parasitemia (p=0.27) on AUC0!3.
Fever and higher temperatures were associated with lower
AUC0!3 values (p=0.02 and p = 0.001, respectively).
Among pregnant women, there was no effect of smoking
(p=0.15) or estimated gestational age on AUC0!3 (Spear-
man’s rho=−0.29, p=0.37). There was no difference in
AUC0!1 between pregnant (n=11) and nonpregnant (n=
11) women (p=0.99) (Fig. 1); on average, the difference in
(log) CQ AUC0!1 between pregnant and nonpregnant
women was only 0.2% (95% CI −0.28 to 40). A lower
AUC0→∞ was associated with higher temperature (p=
0.006) in the univariate analysis but not with hematocrit
(p=0.91), BMI (p=0.36), or parasitemia (p=0.21). Adjust-
ing the model for hematocrit, platelet count, bilirubin, and
temperature made no difference to AUC0!1 between the
groups (p=0.26). For pregnant women (n=11), there was
Table 1 Admission demographics and laboratory variables of 12 pregnant and 13 nonpregnant Karen women with acute Plasmodium vivax
malaria
pregnant nonpregnant P value
Median age (range), years 25 (15–37) 29 (15–40) 0.43
Median gravidity (range) 3 (1–10) 2 (0–8) 0.39
Median parity (range) 2 (0–6) 1 (0–8) 0.96
Mean weight (SD), kg 49.5 (5.6) 46.0 (4.9) 0.11
Mean BMI (SD), kg/m2 21.9 (2.5) 20.0 (2.8) 0.10
Median temperature (range), °C 37.2 (36.5–40) 37.3 (36.5–40) 0.11
Percent febrile (n) 9.1 (1/11)a 38.5 (5/13) 0.17
Percent with headache (n) 66.7 (8/12) 100 (13/13) 0.039
Percent with rigors (n) 0 38.5 (5/13) 0.039
Percent with anorexia (n) 33.3 (4/12) 76.9 (10/13) 0.047
Percent vomiting (n) 0 30.8 (4/13) 0.096
Median estimated gestational age (range), weeks 27.4 (23.0–37.1) - -
Geometric mean (SD) parasitemia, /μl 244 (13.3) 1776 (15.2) 0.08
Mean platelet count (SD), /μl 160.8 (39.2) 129.5 (40.2) 0.06
Mean hematocrit (SD), % 31.2 (2.9) 37.1 (4.5) 0.0005b
Mean white blood cell count (SD), /μl 10.8 (3.0) 9.1 (3.7) 0.23
Mean lymphocytes (SD), % 30 (9.1) 42 (10.4) 0.006
Median bilirubin (range), mg/dl 0.19 (0.08–2.00) 0.53 (0.13–2.20) 0.009
Mean creatinine (SD), mg/dl 0.66 (0.16) 0.78 (0.14) 0.05
Mean BUN (SD), mg% 7.17 (2.4) 10.38 (3.8) 0.02
Mean albumin (SD), g% 3.13 (0.5) 3.69 (0.4) 0.009
BMI body mass index, BUN blood urea nitrogen
a One pregnant woman was missing temperature, b although the distribution did not deviate significantly from normal, the Mann–Whitney U test
was used because of unequal standard deviations (SD)
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no effect of smoking (p=1.0) on AUC0!1 , but a higher
gestational age at entry to the study was associated with a
lower AUC0!1 (Spearman’s rho=−0.67 p=0.02).
Pharmacokinetics of desethylchloroquine
Twowomen (both pregnant) had noDEQmeasurements, which
left ten pregnant and 13 nonpregnant women for comparison.
Cmax and tmax did not differ between pregnant and nonpreg-
nant women (p=0.29 and p=0.33, respectively). The ratio of
CQ to DEQ AUC0!3 was also not different [median 4.89
(range 3.21–6.28) and 4.39 (2.34–8.77), respectively; p=0.66].
In the univariate analysis, the CQ to DEQ AUC0→3 ratio was
significantly correlated with parasitemia on admission (p=
0.003) but not with temperature (p=0.22), fever (p=0.14), or
BMI (p=0.50). Inclusion of parasitemia in the model made no
difference in the CQ to DEQ AUC0!3 ratio between pregnant
and nonpregnant women (p=0.70).
Table 2 Comparison of noncompartmental pharmacokinetic data for chloroquine from day 0 to day 42 in 12 pregnant women and 13
nonpregnant women of child-bearing age with acute vivax malaria. Values are medians (range)
pregnant nonpregnant P value
t1/2 elim (h)* 180.4 (139.4, 926.1) 209.0 (116.5, 1794.0) 0.82
k (h−1)* 0.004 (0.0007, 0.0050) 0.003 (0.0004, 0.006) 0.82
Cmax (ng/ml)** 960.5 (297, 1835) 700 (403, 1625) 0.55
tmax (h)** 3 (1.5, 8) 2 (1.5, 6) 0.17
AUC0!1 (ng/ml · h)* 122 216 (74 145, 269 600) 134 087 (62 940, 229 695) 0.78
CL/F (ml/h/kg)* 209.4 (95.0, 349.1) 189.1 (110.4, 406.6) 0.77
AUC0!3 (ng/ml · h) 33 086 (16 806, 89 285) 27 036 (13 197, 68 040) 0.28
t1/2 elim elimination half-life, k elimination rate constant, Cmax peak whole blood concentration, tmax time to reach Cmax, AUC area under the
whole-blood concentration-time curve, CL/F apparent clearance
* n=11 for pregnant women because one patient had a higher chloroquine concentration at day 42 than day 35, therefore an AUC based on a log
linear fit of the terminal values could not be calculated; n = 11 for nonpregnant women because 2 had levels of chloroquine below the lower limits
of quantification (LLOQ) for the last 4 time points
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Fig. 1 Comparison of mean
[standard error (SE)] whole-
blood chloroquine concentra-
tions in pregnant (dashed line,
triangle markers) and nonpreg-
nant (solid line, square markers)
women with acute vivax malaria
from day 0 to day 3 (inset) to
day 42
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DEQ levels were reliably detected for 14 days. There
was no difference in median AUC0!14 or the median ratio
of CQ to DEQ AUC0!14 between pregnant and nonpreg-
nant women [for median AUC0!14: 29,841 (range 17,533–
46,849) vs. 29,556 (10,145–64,102), p=0.65 and 3.78
(2.42–5.14) vs. 3.50 (2.47–5.48), p=0.41 for median CQ:
DEQ ratio]. The CQ:DEQ AUC0!14 ratio was not
associated with temperature (p=0.72), parasitemia (p=
0.56), fever (p=0.42), or BMI (p=0.86) at admission. In
pregnant women (n=10), the CQ:DEQ AUC0!14 ratio did
not correlate significantly with smoking (p=0.09) or
estimated gestational age (p=0.49) and did not correlate
with the CQ AUC0!14 (Spearman’s rho=0.08, p=0.75).
Discussion
This study found no significant differences in the pharma-
cokinetic parameters of CQ and its main metabolite DEQ in
pregnant women and nonpregnant women treated for acute
vivax malaria. Lower CQ AUC0!1 and AUC0!3 values
were associated with fever on admission, and a lower
AUC0!1 was significantly associated with greater estimat-
ed gestational age. There was also no difference in the DEQ
AUC0!3, AUC0!14 , or CQ:DEQ AUC0!14 ratio between
pregnant and nonpregnant women, although there was wide
interindividual variation in the concentration measurements
between women in both groups.
Previous studies of antimalarial drug pharmacokinetics
have reported lower plasma concentrations in pregnant
women for mefloquine, sulfadoxine, dihydroartemisinin,
artemether, lumefantrine, atovaquone, proguanil, and cyclo-
guanil [1—5]. CQ appears different in that its pharmaco-
kinetic properties are not significantly affected by
pregnancy, although there was evidence that AUC values
decreased as gestation increased, compatible with a
pregnancy-related expansion in the apparent volume of
distribution (Vd). CQ has unusual pharmacokinetic proper-
ties. It has very long terminal half-life and an enormous Vd
[14, 10, 11]. Previous pharmacokinetic studies in pregnancy
measured plasma concentrations, which has limitations, as
CQ is concentrated in platelets and granulocytes and then
variably released from these cells in blood samples [15]. On
the other hand, because large within-group variations can
result in an apparent small between-groups variation, the
wide interindividual variation in CQ concentrations can
make it more difficult to detect moderate to small differ-
ences between groups.
A previous study reported higher plasma DEQ concen-
trations in pregnant women compared with nonpregnant
Nigerian women [11]. Our study found no significant
differences in DEQ for median peak whole-blood concen-
tration, time-to-peak concentration, AUC0!3, or the CQ:
DEQ AUC0!14 ratio among pregnant and nonpregnant
Karen women. The CQ:DEQ AUC0!14 was also not
correlated with CQ AUC0!14 values, which suggests that
metabolic biotransformation was not a major determinant of
CQ clearance.
In conclusion, in this study of Karen women with P.
vivax malaria, pregnancy did not significantly affect blood
concentrations of CQ or its metabolite, DEQ, when
compared with nonpregnant women. Weight-based standard
doses are appropriate for treating malaria in pregnancy.
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